Foghorn Therapeutics Inc.

NASDAQ:FHTX

Biotechnology

Healthcare
$1.79 +2.35%

+$0.10 today

Market cap
$107.33M
Beta
2.89
P/E (TTM)
-3.8
EPS (TTM)
-$1.08
52W Low $3.27High $6.95

Volume 0.53M

Average 0.15M

FHTX Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Foghorn Therapeutics Inc.NASDAQ: FHTX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $238K fell 71.2% year over year, behind the -8.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 72.0% from the prior quarter. Over 3 fiscal years it compounded at -25.0% a year.

Context

  • Depreciation & amortization amounted to 10.8% of revenue in FY2025, down 3.0 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -71.2% toward the trailing-twelve-month pace of -8.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$238K-72.0% QoQ
Last fiscal yearDec 2025
$3.33M+6.8% YoY
LTMMar 2026
$2.84M-8.0% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-71.2%——
1 year+6.8%——
3-year CAGR-25.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
3.33M USD
Year-over-year change
+6.8%
4-year CAGR
+0.8%

Depreciation & Amortization vs competitors

How FHTX compares with its peers on the latest reported figures

  • FHTX's LTM Mar 2026 depreciation & amortization of $2.84M is the 6th largest of the 11 companies compared; the peer median is $1.71M.
  • Its year-over-year change of -8.0% is the 8th highest of 10, against a peer median of +15.1%.
  • Depreciation & amortization amounts to 10.1% of revenue for FHTX, versus a peer median of 6.4%.
FHTX Competitors Peer median
Depreciation & Amortization for FHTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$8.66M +9.7%—4.0%
HUMAHumacyte, Inc.LTM Mar 2026$6.86M +34.4%-13.4%340.1%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$4.95M +56.5%+19.6%7.2%
PYXSPyxis Oncology, Inc.LTM Mar 2026$4.42M +82.7%+85.3%31.9%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$2.88M -16.2%+25.6%6.4%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$2.84M -8.0%-25.0%10.1%
IMRXImmuneering CorporationLTM Mar 2026$531.13K +15.1%-4.3%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$284K -92.5%+29.3%4.9%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$122K -6.2%-36.3%0.2%
ZURAZura Bio LimitedLTM Mar 2026$56K +229.4%——
SGMTSagimet Biosciences Inc.LTM Mar 2026$0 ———
Peer median (excluding FHTX) $1.71M+15.1%+19.6%6.4%

Competitors are the stored peer set for FHTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(101.32M)(108.88M)(98.43M)(86.62M)(74.28M)
Depreciation & Amortization3.23M7.9M3.45M3.12M3.33M
Deferred Income Tax1.41M0000
Stock-Based Compensation8.38M016.19M11.89M10.4M
Change in Working Capital33.44M281.55M(41.88M)(32.27M)(32.14M)
Accounts Receivables(300M)300M000
Inventory(3.17M)0000
Accounts Payables135K1.61M846K(2.48M)481K
Other Working Capital336.48M(20.07M)(42.73M)(29.79M)(32.62M)
Other Non-Cash Items4.61M13.05M2.56M3.47M6.59M
Operating Cash Flow(50.25M)193.61M(118.11M)(100.41M)(86.1M)
Capital Expenditures(3.31M)(1.21M)(1.22M)(906K)(50K)
Acquisitions (Net)(39.49M)0000
Purchases of Investments(99.98M)(409.35M)(73.9M)(261.47M)(131.25M)
Sales of Investments139.47M166.23M219.58M232.47M243.34M
Other Investing Activities39.49M0000
Investing Cash Flow36.17M(244.32M)144.45M(29.9M)112.04M
Debt Repayment(21.21M)0000
Common Stock Issued42.21M1.76M0103.4M1.02M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.42M01.78M2.03M0
Financing Cash Flow22.42M1.76M1.78M105.43M1.02M
Effect of Forex Changes025K000
Net Change in Cash8.34M(48.92M)28.12M(24.88M)26.96M
Free Cash Flow(53.56M)192.4M(119.33M)(101.31M)(86.15M)

Foghorn Therapeutics Inc.

NASDAQ:FHTX

Intrinsic Alpha fair value

Locked

Current Price

$1.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.